Relay Therapeutics, Inc. (RLAY)

NASDAQ: RLAY · Real-Time Price · USD

19.93

-0.14 (-0.70%)

At close: Aug 13, 2026, 4:00 PM EDT

19.99

+0.06 (0.30%)

Pre-market: Aug 14, 2026, 6:01 AM EDT

Relay Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	10.35	15.36	10.01	25.55	1.38	3.03
Revenue Growth	23.86%	53.44%	-60.83%	1749.82%	-54.41%	-96.34%
Gross Profit	10.35	15.36	10.01	25.55	1.38	3.03
Selling, General & Admin	50.06	56.71	76.59	74.95	65.98	57.39
Research & Development	270.72	261.38	319.09	330.02	246.36	295.65
Other Operating Expenses	-	-	-13.21	-6.42	-11.68	14.69
Total Operating Expenses	320.79	318.09	382.48	398.55	300.66	367.73
Operating Income	-310.44	-302.74	-372.47	-373	-299.28	-364.7
Interest Income	24.58	27.04	34.75	31.05	8.79	0.83
Other Non-Operating Income (Expense)	-0.19	-0.78	0.01	-0.02	-0.02	-0
Total Non-Operating Income (Expense)	24.4	26.26	34.76	31.03	8.77	0.83
Pretax Income	-286.04	-276.48	-337.71	-341.97	-290.51	-363.87
Net Income	-286.04	-276.48	-337.71	-341.97	-290.51	-363.87
Net Income to Common	-286.04	-276.48	-337.71	-341.97	-290.51	-363.87
Net Income Growth	-	-	-	-	-	-
Shares Outstanding (Basic)	182	172	143	123	112	95
Shares Outstanding (Diluted)	182	172	143	123	112	95
Shares Change	12.41%	20.10%	16.55%	9.21%	17.97%	123.22%
EPS (Basic)	-1.57	-1.61	-2.36	-2.79	-2.59	-3.82
EPS (Diluted)	-1.57	-1.61	-2.36	-2.79	-2.59	-3.82
EPS Growth	-	-	-	-	-	-
Free Cash Flow	-212.21	-235.87	-251.13	-304.44	-238.55	-77.88
Free Cash Flow Growth	-	-	-	-	-	-
Free Cash Flow Per Share	-1.17	-1.37	-1.76	-2.48	-2.13	-0.82
Gross Margin	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Operating Margin	-2999.37%	-1971.59%	-3722.07%	-1460.11%	-21670.90%	-12040.20%
Profit Margin	-2763.64%	-1800.58%	-3374.72%	-1338.66%	-21036.10%	-12012.90%
FCF Margin	-2050.29%	-1536.08%	-2509.49%	-1191.74%	-17273.90%	-2571.05%
EBITDA	-308.22	-299.18	-367	-367.73	-295.15	-360.77
EBITDA Margin	-2978.01%	-1948.43%	-3667.47%	-1439.49%	-21371.80%	-11910.60%
EBIT	-310.44	-302.74	-372.47	-373	-299.28	-364.7
EBIT Margin	-2999.37%	-1971.59%	-3722.07%	-1460.11%	-21670.90%	-12040.20%

SEC Filings: 10-K · 10-Q